antibiotic commercialization

Biotech startups focused on antimicrobial innovation are redefining how the United States addresses one of the most pressing public health and economic threats of this decade, antimicrobial resistance. As resistant pathogens outpace traditional drug development models, early-stage biotechnology companies are stepping into a space long vacated by large pharmaceutical firms due to weak return profiles … Read more